Jeroan Allison to Antirheumatic Agents
This is a "connection" page, showing publications Jeroan Allison has written about Antirheumatic Agents.
Connection Strength
0.233
-
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun 15; 59(6):762-84.
Score: 0.063
-
Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007 Apr; 56(4):1125-33.
Score: 0.058
-
Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, Allison J, Braun MM. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum. 2007 Mar 15; 57(2):343-6.
Score: 0.058
-
Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf. 2006 Jan; 15(1):11-8.
Score: 0.053